<DOC>
	<DOCNO>NCT02545283</DOCNO>
	<brief_summary>This study design compare Overall Survival ( OS ) participant relapse refractory Acute Myeloid Leukemia ( AML ) treat idasanutlin combination cytarabine versus participant treat placebo cytarabine . Participants receive induction treatment idasanutlin/placebo cytarabine ( Cycle 1 ) . Responding patient may continue receive maximum two cycle consolidation ( Cycle 2 Cycle 3 ) . Complete remission ( CR ) , CR incomplete platelet count recovery ( CRp ) , overall remission rate ( ORR ) , event-free survival ( EFS ) , leukemia-free survival ( LFS ) percentage participant allogeneic hematopoietic stem cell transplant ( HSCT ) also compare treatment arm . This study include participant without ( TP53 wild-type ) TP53 mutation .</brief_summary>
	<brief_title>A Study Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo Patients With Relapsed Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Age &gt; =18 year Documented/confirmed 1st/2nd refractory/relapsed acute myeloid leukemia ( AML ) use World Health Organization classification , except acute promyelocytic leukemia . No 2 prior induction regimen ( exclude prior hematopoietic stem cell transplant [ HSCT ] ) one must include cytarabine anthracycline ( anthracenedione ) Eastern Cooperative Oncology Group performance status 0 1 Patient potential candidate allogeneic HSCT Adequate hepatic renal function Patients first complete remission ( CR1 ) duration &gt; 1 year AND age &lt; 60 year Patients AML myelodysplasia relate change , AML develop consequence antecedent hematological disorder ( AHD ) AML secondary prior chemotherapy unrelated leukemia Patients receive two prior cytarabine contain induction regimen AML Patients relapse within 90 day therapy intermediatedose cytosine arabinoside ( IDAC ) highdose cytosine arabinoside ( HiDAC ) contain regimens Patients receive allogeneic HSCT within 90 day prior randomization . Patients receive immunosuppressive therapy graft versus host disease ( G versus HD ) within 2 week prior study start Prior treatment Murine Double Minute 2 ( MDM2 ) antagonist Patients receive investigational commercial agent therapy administer intention treat malignancy Patients history malignancy within 5 year prior screen . Patients severe and/or uncontrolled medical condition condition could affect participation study Pregnant breastfeeding patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>